Amarpreet Sawhney is the President and CEO of Ocular Therapeutix, Inc. a company focused on unmet needs in ophthalmic surgical wound management and drug delivery. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company, the Chairman of MarketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence, technology founder of Focal, Inc. (acquired by Genzyme) and Access Closure Inc. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He is a member of the board of directors of, Ostial Corp., TiE Boston, Ocular Therapeutix, Augmenix, and Incept LLC and is also a Founder of the last three companies.
Dr. Sawhney has been recognized by several awards including being named the “Five most innovative Medical Device CEOs” by MassDevice, MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, the E&Y regional entrepreneur of the year award, Mass High Tech All Star award, TiE Star award, the University of Texas Outstanding Young Engineering Graduate award, and the Indian Institute of Technology Delhi Distinguished Alumni award. Dr. Sawhney holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi.